Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001218044 | SCV001389911 | uncertain significance | not provided | 2021-09-01 | criteria provided, single submitter | clinical testing | This sequence change replaces phenylalanine with leucine at codon 1022 of the ELP1 protein (p.Phe1022Leu). The phenylalanine residue is moderately conserved and there is a small physicochemical difference between phenylalanine and leucine. This variant is present in population databases (rs372822046, ExAC 0.002%). This variant has not been reported in the literature in individuals affected with ELP1-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004034056 | SCV002755534 | uncertain significance | not specified | 2019-12-03 | criteria provided, single submitter | clinical testing | The p.F1022L variant (also known as c.3066T>A), located in coding exon 27 of the IKBKAP gene, results from a T to A substitution at nucleotide position 3066. The phenylalanine at codon 1022 is replaced by leucine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001836162 | SCV002082044 | uncertain significance | Familial dysautonomia | 2020-07-17 | no assertion criteria provided | clinical testing |